Polyethoxylated castor oil, process of making the same and formu

Details Polyethoxylated castor oil, process of making the same and formu Polyethoxylated castor oil, process of making the same and formu

1997-12-24

1999-07-20

Killos, Paul J.

Organic compounds -- part of the class 532-570 series

Organic compounds

Fatty compounds having an acid moiety which contains the...

514549, 554176, C07C 5900, C07C 5143, A01N 3706

Patent

active

059257768

ABSTRACT:
Polyethoxylated castor oil with a low cation content are claimed, along with particular methods for achieving such low cation content polyethoxylated castor oil. One method of production of such a low cationic content polyethoxylated castor oil according to the invention is to pre-treat the polyethoxylated castor oil with a strong cationic exchange resin to remove a substantial portion of the cations present in an untreated polyethoxylated castor oil. The low cationic content polyethoxylated castor oil of the invention can then be utilized to prepare formulations of various agents which are found to be sensitive to the previously commercially available polyethoxylated castor oil (CREMOPHOR EL.RTM.).

REFERENCES:
patent: 4960799 (1990-10-01), Nagy
patent: 5015744 (1991-05-01), Holton
patent: 5407683 (1995-04-01), Shively
patent: 5415869 (1995-05-01), Staubinger et al.
patent: 5438072 (1995-08-01), Bobee et al.
patent: 5462726 (1995-10-01), Lodge
patent: 5504102 (1996-04-01), Agharkar et al.
patent: 5681846 (1997-10-01), Trissel
Engel et al, "High Performance Liquid Chromatographic Analysis (HPLC) and Human Pharmacokinetics of Taxol (NSC 125973)", Proc. of AACR, vol. 26, Mar. 1989, p.158, Abstract #625 pp. 59-64 (1991).
Kingston, David, "The Chemistry of Taxol", Pharmac. Ther. vol. 52, 1-34, 1991.
Kingston et al., "Synthesis and Structure--Activity Relationships of Taxol Derivatives as Anticancer Agents", New Trends in Natural Products Chemistry 1986, vol. 26, 219-235.
Richheimer et al., "High-Performance Liquid Chromatographic Assay of Taxol", Anal. Chem. 1992, vol. 64, 2323-2326.
Ringel et al., "Taxol is Converted to 7-Epitaxol, a Biologically Active Isomer, in Cell Culture Medium", Journal of Pharmacology and Experimental Therapeutics, vol. 242, 1987, 692-698.
Rizzo et al., "Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics", Journal of Pharmaceutical & Biomedical Analysis (1990), vol. 8(2), pp. 159-164.
Waugh et al., "Stability, compatability, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions stored in various containers", AHJP vol. 48, Jul. 1991, 1520-1524.
Wiernik et al., "Phase I Trial of Taxol Given as a 24-Hour Infusion Every 21 Days: Response observed in Metastatic Melanoma", Journal of Clinical Oncology, vol. 5, No. 8, pp. 1232-1239 (Aug. 1987).
Chabner, "Taxol", Principles & Practice of Oncology (1991) 5:1-10 No. 9.
Collins-Gold et al., "Parenteral emulsions for drug delivery", Advanced Drug Delivery Reviews, 5 (1990) 189-208.
Donehower et al., "Phase I Trial of Taxol in Patients With Advanced Cancer", Cancer Treatment Reports vol. 71. No. 12, Dec. 1987, 1171-1177.
Einzig et al., "Phase II Trial of Taxol in Patients with Metastatic Renal Cancer Carcinoma", Cancer Investigation, 9(2) 133-136 (1991).
Einzig et al., "A phase II study of taxol patients with malignant melanoma", Investigational New Drugs 9, pp. 59-64 (1991).
Holmes et al., "Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer", Journal of the National Cancer Institute 83:1797-1805 No. 24 (1989).
Kris et al., "Phase I Trial of Taxol Given as a 3-hour Infusion Every 21 Days", Cancer Treatment Reports, vol. 70, May 1986, pp.605-607.
Rose, William, "Taxol: a review of its preclinical in vivo antitumor activity", Anti-Cancer Drugs, vol. 3, 311-321, 1992.
Trissel et al., "compounding an Extended-Stability Admixture of Paclitaxel for Long-Term Infusion", International J. of Pharmaceutical Compounding, vol. 1, No. 1, Jan./Feb. 1997, pp. 49-53.
Room Temperature Stability of Taxol.RTM., Bristol-Myers Squibb Oncology/Immunology--2 pages.
BASF, Products for the pharmaceutical Industry, Technical Information, ME 148 e (985) Nov. 1996 (JWF) pp. 1-15.
BASF, Cremophor.RTM. EL, Technical Leaflet, pp. 1-5.
BASF, Preliminary specification Cremophor.RTM. EL-P, Mar. 1995 (1 page).
Handbook of Pharmaceutical Excipients 1986 pp. 221-224.

Affiliated with

Also associated with

Rating

Polyethoxylated castor oil, process of making the same and formu does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polyethoxylated castor oil, process of making the same and formu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyethoxylated castor oil, process of making the same and formu will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1323101